Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows

Arena Pharmaceuticals, Inc. (ARNA - Snapshot Report) reported a net loss (excluding one-time items) of 13 cents per share in the third quarter of 2014 in line with the Zacks Consensus Estimate but wider than the year-ago loss of 10 cents per share. The company’s share fell 3.2% following the news.

Arena Pharma recorded third-quarter revenues of $8.2 million, below the Zacks Consensus Estimate of $10 million. Revenues however shot up 128.2% from the year-ago quarter.

Third-quarter 2014 research and development (R&D) and general and administrative (G&A) expenses were up 68% to $24.5 million and 3.5% to $8 million, respectively.

Belviq Update

Arena Pharma recorded Belviq sales of $5.7 million (including $0.5 million from the 15-day free trial voucher redemption) compared with $2 million in the third quarter of 2013. Arena Pharma is working on expanding the market reach of Belviq.

We note that Arena Pharma has a collaboration agreement with Eisai Co., Ltd. (ESALY) for Belviq.

Eisai recorded net product sales of $16.8 million for Belviq in the third quarter of 2014. Total prescriptions for Belviq increased 30% from the preceding quarter to more than 143,000.

Arena Pharma and Eisai are leaving no stone unturned to make the drug a success. Eisai added 200 representatives to the existing sales force of approximately 400 for Belviq.

Arena Pharma and Eisai are evaluating Belviq for additional indications. The companies are evaluating Belviq for smoking cessation in a phase II study, top-line results of which have recently been announced. Results from the study demonstrated a statistically significant improvement in reducing the number of patients who smoke after 12 weeks of Belviq treatment as compared to placebo.

Arena Pharma and Eisai are also studying Belviq for weight management in combination with phentermine in a 12-week pilot study. Top-line results from the study showed that the short-term combination of Belviq and phentermine does not appear to be associated with an exacerbation in the proportion of pre-specified adverse events when compared to lorcaserin alone. Additionally, Arena Pharma initiated two phase I studies evaluating Belviq 20 mg extended release tablets in children.

1 2
View single page >> |

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. more

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.